Trial Profile
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' After Intramuscular Administration in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Il-Yang Flu vaccine quadrivalent (Primary) ; IL Yang Flu Vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Il-Yang
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 15 Feb 2016 New trial record